US-Abraham Accords Cooperation: New FDA Office for Medical Products and Security
This Act establishes a new Abraham Accords Office within the U.S. Food and Drug Administration (FDA) to promote and facilitate cooperation with entities in Abraham Accords countries. The primary goal is to help these foreign companies meet U.S. regulatory standards for manufacturing and approval of drugs and medical devices, enabling them to sell products in the United States. This initiative aims to diversify the supply chain and potentially increase the availability of medical products for U.S. consumers, while maintaining strict FDA oversight.
Key points
Establishes the Abraham Accords Office within the FDA to foster collaboration on medical products with countries that signed the Abraham Accords.
The Office will provide technical assistance on good manufacturing practices (GMP) and regulatory pathways to help foreign entities gain FDA approval for drugs and devices.
Potential benefit for citizens is increased competition and supply of medical products, ensuring they meet U.S. safety and quality standards.
The Secretary has the authority to suspend the Office's activities for up to 6 months if deemed necessary for U.S. national security interests.
Expired
Citizen Poll